World's Best Scientists 2026 revealed!
Liver Cancer
H-index 40

Liver Cancer

2235-1795

Published by: Karger Publishers

https://www.karger.com/Journal/Home/255487

Ranking & Metrics

Discipline name Position Best Scientists Publications D-Index
Medicine 435 130 155 38

Additional Metrics

Number of Best Scientists*: 180
Documents by Best Scientists*: 173
Top 100 Ranked Scientists*: 4
SCIMAGO H-index: 63
SCIMAGO SJR: 2.779
Impact Factor: 9.1

Overview

Top Research Topics at Liver cancer?

The journal explores disciplines such as Hepatocellular carcinoma, Internal medicine, Oncology, Gastroenterology and Sorafenib. Liver cancer studies in the realm of Hepatocellular carcinoma interact with fields like In patient. Liver cancer research presented falls under the umbrella topic of Cancer.

Lenvatinib, Hazard ratio, Clinical trial, Stage (cooking) and Cirrhosis are among the areas of Internal medicine tackled. Research on Oncology addressed in the journal frequently intersections with the field of Regorafenib. Some problems in Gastroenterology that were presented in the journal overlapped with concepts under Liver transplantation and Cohort.

The journal explores studies in Liver transplantation as part of the wider topic of Transplantation. Sorafenib study tackled is connected to the field of Surgery. Liver cancer investigates Radiology research which frequently intersects with Radiofrequency ablation.

  • Hepatocellular carcinoma (58.05%)
  • Internal medicine (43.74%)
  • Oncology (22.86%)

What are the most cited papers published in the journal?

  • JSH Consensus-Based Clinical Practice Guidelines for the Management of Hepatocellular Carcinoma: 2014 Update by the Liver Cancer Study Group of Japan (357 citations)
  • Guidelines for Diagnosis and Treatment of Primary Liver Cancer in China (2017 Edition). (230 citations)
  • Treatment of hepatocellular carcinoma: a systematic review. (211 citations)

Research areas of the most cited articles at Liver cancer:

The most cited papers tackle a plethora of topics, such as Hepatocellular carcinoma, Internal medicine, Oncology, Pathology and Gastroenterology. The journal papers facilitate discussions on Hepatocellular carcinoma that incorporate concepts from other fields like Radiology, Cancer and Surgery. The journal papers cover research in Internal medicine, particularly Cirrhosis, Transplantation, Stage (cooking) and Liver function and how it is related with concepts in In patient.

What topics the last edition of the journal is best known for?

  • Cancer
  • Internal medicine
  • Surgery

The previous edition focused in particular on these issues:

The topics of Hepatocellular carcinoma, Internal medicine, Oncology, In patient and Gastroenterology are the focal point of discussions in the journal. Hepatocellular carcinoma studies tackled cover an aspect of the field of Cancer research. The Internal medicine research presented places emphasis on topics like Sorafenib, Lenvatinib, Atezolizumab, Bevacizumab and Hazard ratio.

Aside from discussions in Sorafenib, it also deals with the subject of Clinical trial which intersects with Nivolumab, Performance status, Cabozantinib and Randomized controlled trial disciplines. The featured Oncology research zeroes in on concepts in Adjuvant but also tackles themes under Intermediate stage. The presented studies in Liver function fall within the purview of Gastroenterology but it also intertwines with topics in Entecavir, Tenofovir and Akaike information criterion.

The most cited articles from the last journal are:

  • Clinical-Radiomic Analysis for Pretreatment Prediction of Objective Response to First Transarterial Chemoembolization in Hepatocellular Carcinoma (7 citations)
  • Clinical outcomes with multikinase inhibitors after progression on first-line atezolizumab plus bevacizumab in patients with advanced hepatocellular carcinoma: A multinational, multicenter retrospective study. (4 citations)
  • Immunological Microenvironment Predicts the Survival of the Patients with Hepatocellular Carcinoma Treated with Anti-PD-1 Antibody. (3 citations)

Papers citation over time

A key indicator for each journal is its effectiveness in reaching other researchers with the papers published at that venue.

The chart below presents the interquartile range (first quartile 25%, median 50% and third quartile 75%) of the number of citations of articles over time.

The top authors publishing in Liver cancer (based on the number of publications) are:

  • Masatoshi Kudo (92 papers) published 13 papers at the last edition, 2 less than at the previous edition,
  • Norihiro Kokudo (26 papers) published 2 papers at the last edition, 1 more than at the previous edition,
  • Ann-Lii Cheng (16 papers) published 3 papers at the last edition, 1 more than at the previous edition,
  • Takashi Kumada (16 papers) published 1 paper at the last edition, 3 less than at the previous edition,
  • Atsushi Hiraoka (13 papers) published 2 papers at the last edition, 2 less than at the previous edition.

The overall trend for top authors publishing in this journal is outlined below. The chart shows the number of publications at each edition of the journal for top authors.

Only papers with recognized affiliations are considered

The top affiliations publishing in Liver cancer (based on the number of publications) are:

  • Kindai University (71 papers) published 9 papers at the last edition, 6 less than at the previous edition,
  • National Taiwan University (26 papers) published 4 papers at the last edition, 1 less than at the previous edition,
  • University of Tokyo (24 papers) published 3 papers at the last edition, 1 less than at the previous edition,
  • University of Bologna (15 papers) published 4 papers at the last edition, 3 more than at the previous edition,
  • Yonsei University (13 papers) absent at the last edition.

The overall trend for top affiliations publishing in this journal is outlined below. The chart shows the number of publications at each edition of the journal for top affiliations.

Publication chance based on affiliation

The publication chance index shows the ratio of articles published by the best research institutions in the journal edition to all articles published within that journal. The best research institutions were selected based on the largest number of articles published during all editions of the journal.

The chart below presents the percentage ratio of articles from top institutions (based on their ranking of total papers).Top affiliations were grouped by their rank into the following tiers: top 1-10, top 11-20, top 21-50, and top 51+. Only articles with a recognized affiliation are considered.

During the most recent 2021 edition, 38.89% of publications had an unrecognized affiliation. Out of the publications with recognized affiliations, 69.70% were posted by at least one author from the top 10 institutions publishing in the journal. Another 0.00% included authors affiliated with research institutions from the top 11-20 affiliations. Institutions from the 21-50 range included 24.24% of all publications and 6.06% were from other institutions.

Returning Authors Index

A very common phenomenon observed among researchers publishing scientific articles is the intentional selection of journals they have already attended in the past. In particular, it is worth analyzing the case when the authors participate in the same journal from year to year.

The Returning Authors Index presented below illustrates the ratio of authors who participated in both a given as well as the previous edition of the journal in relation to all participants in a given year.

Returning Institution Index

The graph below shows the Returning Institution Index, illustrating the ratio of institutions that participated in both a given and the previous edition of the conference in relation to all affiliations present in a given year.

The experience to innovation index

Our experience to innovation index was created to show a cross-section of the experience level of authors publishing in a journal. The index includes the authors publishing at the last edition of a journal, grouped by total number of publications throughout their academic career (P) and the total number of citations of these publications ever received (C).

The group intervals were selected empirically to best show the diversity of the authors' experiences, their labels were selected as a convenience, not as judgment. The authors were divided into the following groups:

  • Novice - P < 5 or C < 25 (the number of publications less than 5 or the number of citations less than 25),
  • Competent - P < 10 or C < 100 (the number of publications less than 10 or the number of citations less than 100),
  • Experienced - P < 25 or C < 625 (the number of publications less than 25 or the number of citations less than 625),
  • Master - P < 50 or C < 2500 (the number of publications less than 50 or the number of citations less than 2500),
  • Star - P ≥ 50 and C ≥ 2500 (both the number of publications greater than 50 and the number of citations greater than 2500).

The chart below illustrates experience levels of first authors in cases of publications with multiple authors.

Career Opportunities in the Field

While this article explores the research side of Hepatocellular carcinoma and liver cancer extensively, it's pivotal not to forget about the practical applications of these studies and health sector contributions. Numerous professionals, including doctors, nursing specialists, and medical researchers, are vital contributors to advancements in this field.

Take, for instance, the nursing profession. Nurses play an important role in implementing daily care plans for liver cancer patients. They provide health education, manage symptoms, comfort patients, and assist with medical procedures. Hence, their role in managing Hepatocellular carcinoma is instrumental. Becoming a qualified nurse specializing in liver cancer treatment and care can be an impactful career choice for those who want to make a difference in this field.

For instance, to gain an insight into the steps of becoming a nurse in the state of Maryland, you can refer to our detailed guide how to become a nurse in Maryland. This resource will provide you with a roadmap, including necessary requirements and potential career paths within the field.

Hence, those in the medical field or aspiring to join it can make meaningful contributions to the study and management of liver cancer, unfolding many career opportunities with the growth of research in this field.

Top Publications

  • Guidelines for the Diagnosis and Treatment of Hepatocellular Carcinoma (2019 Edition).

    Jian Zhou;Huichuan Sun;Zheng Wang;Wenming Cong

    (2020)
    597 Citations
  • Management of Hepatocellular Carcinoma in Japan: JSH Consensus Statements and Recommendations 2021 Update.

    Masatoshi Kudo;Yusuke Kawamura;Kiyoshi Hasegawa;Ryosuke Tateishi

    (2021)
    449 Citations
  • A Changing Paradigm for the Treatment of Intermediate-Stage Hepatocellular Carcinoma: Asia-Pacific Primary Liver Cancer Expert Consensus Statements

    Masatoshi Kudo;Kwang Hyub Han;Sheng Long Ye;Jian Zhou

    (2020)
    213 Citations
  • Surgery versus Radiofrequency Ablation for Small Hepatocellular Carcinoma: A Randomized Controlled Trial (SURF Trial)

    (2021)
    178 Citations
  • Downstaging and Resection of Initially Unresectable Hepatocellular Carcinoma with Tyrosine Kinase Inhibitor and Anti-PD-1 Antibody Combinations.

    Xiao-Dong Zhu;Cheng Huang;Ying-Hao Shen;Yuan Ji

    (2021)
    166 Citations
  • Final Results of TACTICS: A Randomized, Prospective Trial Comparing Transarterial Chemoembolization Plus Sorafenib to Transarterial Chemoembolization Alone in Patients with Unresectable Hepatocellular Carcinoma

    (2022)
    122 Citations
  • Chinese Expert Consensus on Multidisciplinary Diagnosis and Treatment of Hepatocellular Carcinoma with Portal Vein Tumor Thrombus (2018 Edition).

    Shuqun Cheng;Minshan Chen;Jianqiang Cai;Juxian Sun

    (2020)
    115 Citations
  • Exploring Markers of Exhausted CD8 T Cells to Predict Response to Immune Checkpoint Inhibitor Therapy for Hepatocellular Carcinoma

    Chia-Lang Hsu;Da-Liang Ou;Li-Yuan Bai;Chia-Wei Chen

    (2021)
    98 Citations
  • Atezolizumab plus Bevacizumab versus Sorafenib in the Chinese Subpopulation with Unresectable Hepatocellular Carcinoma: Phase 3 Randomized, Open-Label IMbrave150 Study.

    Shukui Qin;Zhenggang Ren;Yin-Hsun Feng;Thomas Yau

    (2021)
    88 Citations
  • Liver Cancer Study Group of Japan Clinical Practice Guidelines for Intrahepatic Cholangiocarcinoma

    (2022)
    85 Citations

Related Online Degrees & Career Pathways

For those interested in Medicine in the USA, exploring related online degrees can broaden career options and enhance expertise. Nursing is a crucial field with many pathways, including the online ASN programs, which offer flexible access to foundational nursing education and prepare students for registered nurse roles.

Nutrition science is another vital area complementing medical studies. Students can advance their understanding through the best online nutrition programs, focusing on diet, health promotion, and disease prevention, crucial for holistic patient care.

Healthcare administration also plays a pivotal role behind the scenes. Aspiring leaders often pursue the top online MHA programs that are CAHME accredited, ensuring quality education in managing healthcare systems effectively.

For advanced clinical practice, many nurses opt for online degree pathways like the MSN to DNP online no clinicals, enabling progression to a Doctor of Nursing Practice degree with minimal onsite clinical requirements, ideal for working professionals.

Best Scientists Contributing to This Journal